MedPath

IX BIOPHARMA LTD.

IX BIOPHARMA LTD. logo
🇸🇬Singapore
Ownership
Public
Established
2008-01-01
Employees
68
Market Cap
-
Website
http://www.ixbiopharma.com

Clinical Trials

8

Active:0
Completed:8

Trial Phases

2 Phases

Phase 2:4
Phase 3:1

Drug Approvals

2

HSA:2

Drug Approvals

SILCAP® 25 CAPSULE 25MG

Approval Date
Oct 9, 2020
HSA

SILCAP® 50 CAPSULE 50MG

Approval Date
Oct 9, 2020
HSA

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (80.0%)
Phase 3
1 (20.0%)

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

Phase 2
Completed
Conditions
Abdominoplasty
Acute Pain
Bunion
Interventions
Drug: Placebos
Drug: Wafermine™ 50 mg
Drug: Wafermine™ 75 mg
Drug: Wafermine™ 25 mg
First Posted Date
2017-08-11
Last Posted Date
2018-07-23
Lead Sponsor
iX Biopharma Ltd.
Target Recruit Count
125
Registration Number
NCT03246971
Locations
🇺🇸

Lotus Clinical Research, Pasadena, California, United States

Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.

Phase 2
Completed
Conditions
Pain
Interventions
First Posted Date
2016-08-05
Last Posted Date
2016-08-19
Lead Sponsor
iX Biopharma Ltd.
Target Recruit Count
10
Registration Number
NCT02857361
Locations
🇦🇺

Linear Clinical Research, Nedlands, Western Australia, Australia

A Pivotal Study of the Bioequivalence of Oral Viagra® and a Test Sublingual Sildenafil Wafer

Phase 3
Completed
Conditions
Erectile Dysfunction
Interventions
First Posted Date
2016-08-01
Last Posted Date
2016-08-19
Lead Sponsor
iX Biopharma Ltd.
Target Recruit Count
48
Registration Number
NCT02850718
Locations
🇦🇺

Linear Clinical Research, Perth, Western Australia, Australia

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

Phase 2
Completed
Conditions
Acute Pain
Interventions
Drug: Wafermine
Drug: Placebo
First Posted Date
2015-09-04
Last Posted Date
2016-02-23
Lead Sponsor
iX Biopharma Ltd.
Target Recruit Count
72
Registration Number
NCT02541396
Locations
🇺🇸

Jean Brown Research, Salt Lake City, Utah, United States

Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction

Phase 2
Completed
Conditions
Pain
Interventions
Drug: Placebo (for Ketamine)
First Posted Date
2015-02-06
Last Posted Date
2015-03-26
Lead Sponsor
iX Biopharma Ltd.
Target Recruit Count
80
Registration Number
NCT02356965
Locations
🇺🇸

Jean Brown Research, Salt Lake City, Utah, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.